📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

A new pragmatic design for dose escalation in phase 1 clinical trials using an adaptive continual reassessment method. (2019)

First Author: North B

Attributed to: MICA: Early phase clinical trial repurposing ATRA as stromal targeting agent in a novel drug combination for pancreatic cancer (STAR-PAC) funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1186/s12885-019-5801-3

PubMed Identifier: 31242873

Publication URI: http://europepmc.org/abstract/MED/31242873

Type: Journal Article/Review

Volume: 19

Parent Publication: BMC cancer

Issue: 1

ISSN: 1471-2407